IGC Pharma Highlights Publication Of Caregiver Book On Alzheimer's Disease

Benzinga · 3d ago

This book represents an essential contribution to the global Alzheimer's community," said Ram Mukunda, CEO of IGC Pharma. "Our diverse pipeline of candidates, including IGC-AD1, currently advancing through the Phase 2 CALMA trial for agitation in Alzheimer's dementia, demonstrates how we are translating scientific innovation into potential treatments, and this book complements those efforts by supporting broader community engagement and awareness as we move toward commercialization."